下跌2610.77%！深圳知名公司披露业绩

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. reported significant declines in revenue and net profit for the first half of 2025, indicating severe pressure on its core business operations [1][2][3] Financial Performance - The company achieved revenue of 1.631 billion yuan, a decrease of 12.82% compared to 1.871 billion yuan in the same period last year [1] - Net profit attributable to shareholders was only 5.7782 million yuan, a sharp decline of 68.25% year-on-year [1] - Excluding non-recurring gains and losses, the net profit turned into a loss of 30.4881 million yuan, a staggering decline of 2610.77% [1] - The net cash flow from operating activities was -414 million yuan, a decrease of 414.23% year-on-year, indicating worsening cash flow conditions [1] Business Segment Performance - The reproductive health segment, a core pillar of the company, reported revenue of 426 million yuan, down 29.80% year-on-year, primarily due to a 35% decline in non-invasive prenatal genetic testing revenue [1][2] - The oncology and chronic disease prevention segment generated revenue of 180 million yuan, a decrease of 27.52%, with colorectal cancer testing revenue dropping approximately 42% [2] - The multi-omics and synthesis segment saw revenue of 279 million yuan, down 8.30%, with RNA product and synthesis revenue declining by about 34% and 29%, respectively [2] Growth Opportunities - The precision medicine testing comprehensive solution business achieved revenue of 696 million yuan, a year-on-year increase of 4.80%, marking it as the only segment with positive growth [3] - The infection prevention business maintained revenue of 38 million yuan, remaining stable compared to the previous year, with PTseq series products showing a remarkable revenue growth of approximately 242% [3] Market Challenges - The company faces challenges from macroeconomic market changes and geopolitical factors, alongside shrinking profit margins in core businesses [3] - The company has not proposed a profit distribution plan, reflecting a cautious outlook on future operations [3] Shareholder Actions - A major shareholder, Shenzhen Shenghua Investment Enterprise, plans to reduce its stake by up to 1.5% over the next three months due to personal funding needs, which may add uncertainty to the company's short-term stock price and future development [4][5]